{"analyses":[{"ciLowerLimit":"0.43","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.86","groupIds":["OG000","OG001"],"nonInferiorityComment":"Unstratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.0047","paramType":"Hazard Ratio (HR)","paramValue":"0.60","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.71","upperLimit":"7.13","value":"5.49"},{"groupId":"OG001","lowerLimit":"7.33","upperLimit":"9.66","value":"8.48"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"78"},{"groupId":"OG001","value":"109"}],"units":"Participants"}],"description":"DOR was defined for participants who had an objective response as the time from the first occurrence of a documented unconfirmed response (CR or PR) to the date of disease progression per RECIST v1.1 or death from any cause, whichever occurred first.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants assigned to placebo plus nab-paclitaxel received both agents until disease progression or unacceptable toxicity.","id":"OG000","title":"Placebo Plus Nab-Paclitaxel"},{"description":"Participants assigned to atezolizumab plus nab-paclitaxel received both agents until disease progression or unacceptable toxicity.","id":"OG001","title":"Atezolizumab Plus Nab-Paclitaxel"}],"paramType":"NUMBER","populationDescription":"The duration of response (DOR)-evaluable population is defined as patients with an objective response.","reportingStatus":"POSTED","timeFrame":"Baseline up to approximately 34 months","title":"DOR Acccording to RECIST v1.1 in Participants With Detectable PD-L1","type":"SECONDARY","unitOfMeasure":"Months"}